Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open‐Label Randomized Clinical Trial
Journal of Gastroenterology and Hepatology · 2026-08 · 41 (8) · 2458-2466
DOI: 10.1111/jgh.70554 ↗At a glance
Randomisierte kontrollierte Studie in Journal of Gastroenterology and Hepatology, published online on 2026-07-07. Written by Chengmei He and 7 co-authors. Institution: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical…. Major MEDLINE topics: Ursodeoxycholic Acid, Liver Cirrhosis, Biliary, Cholagogues and Choleretics, Drug Tapering. 22 references. The full text is freely available in PubMed Central. Funded by: CAMS Innovation Fund for Medical Sciences, Non-profit Central Research Institute Fund of Chinese Academy of Medical Science, Capital Health development Research Special Fund.
Abstract (original language)
Background and Aim Ursodeoxycholic acid (UDCA) is first‐line therapy for primary biliary cholangitis (PBC), evidence for dose reduction after biochemical remission remains limited. This study aimed to evaluate the feasibility and safety of UDCA reduction in PBC.
Methods
In this open‐label randomized controlled clinical trial, PBC patients who reached complete biochemical response (Paris‐II criteria) after ≥ 6 months of standard 13–15 mg/kg/day UDCA therapy were prospectively enrolled. Eligible patients were assigned in a 1:1:1 ratio to receive either (1) continued 13–15 mg/kg/day, (2) 10 mg/kg/day, or (3) 5‐mg/kg/day UDCA. The primary endpoint was biochemical relapse rate within 12 months. Secondary endpoints included changes in liver biochemistry, changes in patient‐reported symptoms, and changes in GLOBE and UK‐PBC scores, as well as adverse events.
Results
From January 2020 to March 2024, 96 patients who complied with the protocol after randomization were analyzed. Within the 12‐month follow‐up period, the relapse rates in the three groups were 0%, 2.9%, and 19.4%, respectively (overall p = 0.008). Secondary outcomes showed no significant intergroup differences. In patients with a disease relapse, prompt retreatment with a standard dose of UDCA could help liver function recover. No severe adverse events were observed.
Conclusions
The relapse rate in the 5‐mg/kg/day group was significantly higher than that in the standard‐dose group, necessitating close clinical monitoring, and no significant difference in relapse was observed between the 10 mg/kg/day and standard‐dose group, suggesting it may be a potential dose‐reduction strategy, though further studies are needed for confirmation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Mini…
- Department of Ultrasound, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Medical Science and Technology Evaluation, Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID profiles: Chengmei He, Yi Wei, Li Wang
Funding
- CAMS Innovation Fund for Medical Sciences
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Science
- Capital Health development Research Special Fund
- Postdoctoral Fellowship Program of CPSF
Cite
APA
He, C., Wei, Y., Zheng, K., Wang, X., Liu, J., Li, M., Wang, L., & Zhang, F. (2026). Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open‐Label Randomized Clinical Trial. Journal of Gastroenterology and Hepatology, 41(8), 2458-2466. https://doi.org/10.1111/jgh.70554
Vancouver
He C, Wei Y, Zheng K, Wang X, Liu J, Li M, et al. Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open‐Label Randomized Clinical Trial. Journal of Gastroenterology and Hepatology. 2026;41(8):2458-2466. doi:10.1111/jgh.70554
BibTeX
@article{He2026,
author = {He, Chengmei and Wei, Yi and Zheng, Kunyu and Wang, Xu and Liu, Jia and Li, Mengtao and Wang, Li and Zhang, Fengchun},
title = {Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open‐Label Randomized Clinical Trial},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {8},
pages = {2458--2466},
doi = {10.1111/jgh.70554}
}
EUVIMED